TrialDiabetes, obesity & metabolism2019

Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.

Yehuda Handelsman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.